Benitec Biopharma: ASX Investor Series (Syd, Oct 2014)

Company Presentations

Benitec Biopharma Limited (ASX:BLT)Chief Business Officer Carl Stubbingspresents at the ASX Investor Series in Sydney.  
 
The biotechnology company working on gene silencing therapies for a range of debilitating illnesses and its treatments for HIV has been approved for stage 2 trials in the US.
 
Mr Stubbings’ presentation is titled, “Gene Silencing: A quiet revolution in healthcare” and covers the company’s investment case, value proposition and recent highlights. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.